Clean water is one of those themes that sounds unarguable as an Investment case and turns out to be maddeningly difficult to make money from. MyCelx Technologies Corporation (LSE:MYX), a US-based specialist in hydrocarbon removal and produced-water treatment, is a case study in both the promise and the pitfalls. The shares nudged higher on 26 August 2026, and while the day's move was modest, it comes after a year in which the company has done something small-cap water-technology businesses rarely manage: turn a profit. Whether that marks the start of a durable re-rating, or simply another twitch in a thinly traded stock, is the question worth interrogating.

What Happened to MyCelx Technologies Shares?

On 26 August 2026 MyCelx (LSE:MYX) shares were up around 2.02% at 50.5p, giving the company a Market Capitalisation of roughly £12.06m. That was enough to place it among the day's stronger AIM performers, but context matters. A 2% move on a stock of this size, with the tight spreads and low free float typical of micro-caps, can be driven by a single modest order rather than any fresh news. There was no price-sensitive announcement from the company on the day itself. In other words, this was a quiet grind higher rather than a genuine "jump", and investors should treat the move as sentiment catching up with recent fundamentals rather than a reaction to a specific catalyst.

Latest Company Developments

The most substantive recent news came in the trading update published on 30 July 2026. Management pointed to what it called the "largest and highest-quality opportunity pipeline in Company history", stating that pipeline opportunities had more than doubled since January 2026 in both number and aggregate value. The active markets named were onshore and offshore produced-water treatment across the US and Middle East, alongside emerging applications in PFAS ("forever chemicals") and industrial water.

Two contract developments underpin the near-term story. First, a $3.9m produced-water treatment project in the Permian Basin, originally announced in November 2025, with Revenue from the REGEN system delivery expected to be recognised in the third quarter of 2026 with a major Midstream operator. Second, in May 2026 the company announced a Gulf of Mexico Lease award with a global integrated oil company — its third offshore produced-water contract in the region. That lease is expected to contribute roughly $850,000 in FY2026 and around $1.5m on a full annual basis, and is structured as recurring monthly rental income plus filtration media sales — the higher-quality, repeat revenue MyCelx has been trying to build.

Financial Performance

The headline numbers for the year ended 31 December 2025 were genuinely strong. Revenue rose 140% to $11.7m (2024: $4.9m). Gross Profit reached $5.6m at a 48% gross margin, up sharply from 27% the prior year. Crucially, the Business swung to positive EBITDA of $0.7m from a $2.2m loss, and delivered a net profit of $0.334m against a $2.7m loss in 2024 — equivalent to basic Earnings of $0.01 per share.

The half-year picture is more sober and a reminder of how lumpy this business is. The 30 July update indicated H1 2026 revenue of approximately $2.1m, up 24% on the $1.7m recorded in H1 2025, driven by paid trials, leases and recurring media sales. That is solid year-on-year growth, but it is a fraction of the annual run-rate, precisely because MyCelx's revenue is skewed towards large, discrete equipment deliveries. Management reaffirmed a full-year 2026 revenue forecast of $11.0m, saying roughly 80% was already booked, contracted or expected through recurring lease and media sales — an implied and demanding second-half weighting.

The Balance Sheet is where caution is warranted. Cash stood at just $0.5m at 30 June 2026, though management noted a further $1.1m of customer payments arrived in July. Year-end 2025 cash was $0.9m, and the group has a modest $0.5m line of credit, of which $0.45m was drawn. This is a business operating with a thin Liquidity cushion relative to the scale of the projects it is chasing.

The Growth Story

The bull case is straightforward. Produced water — the vast Volume of contaminated water brought up alongside oil and gas — is a growing and regulated problem, and tightening rules around water reuse, disposal and PFAS give MyCelx's filtration media a structural tailwind. The strategic shift towards recurring lease and media revenue, visible in the Gulf of Mexico contracts, is exactly what would justify a higher rating: it smooths the lumpiness and improves earnings visibility. A doubled pipeline, a return to profitability and a reaffirmed forecast together sketch an inflection story that a patient investor might find compelling at a £12m valuation.

Risks Investors Should Watch

The risks are equally clear. Revenue remains project-driven and concentrated, so a single delayed delivery — such as the Q3-weighted Permian recognition — can swing a full-year outcome. The $0.5m period-end cash position offers little Margin for error if payments slip. Customer concentration is high, with a handful of oil-and-gas majors driving results, and the group's fortunes are tied to Upstream capital spending and the oil-price cycle. The stock's illiquidity cuts both ways: it can amplify gains, but it can leave holders stranded on the way down. And the 80%-covered FY2026 forecast still leaves a meaningful slice of revenue to be won or recognised in the second half.

What Could Drive the Shares Next?

The clearest near-term catalyst is confirmation that the $3.9m Permian project revenue lands in the third quarter as guided; delivery there would validate the full-year forecast and de-risk the second-half weighting. Beyond that, watch for pipeline conversion — turning that doubled opportunity list into signed leases and media contracts — and for interim results, which should show whether Recurring Revenue is genuinely building. Any new offshore or Middle East award, or a first material PFAS/industrial contract, would speak to Diversification beyond oil and gas. Conversely, a fund-raising to shore up the balance sheet would be a realistic possibility that existing holders should Factor in.

The Bottom Line

MyCelx has delivered the rarest thing for a clean-water micro-cap: a profitable year and a demonstrably growing pipeline. The 26 August move itself was slight and had no specific trigger. The investment question is not whether clean water is a good theme — it plainly is — but whether this particular company can convert a thin balance sheet and lumpy order book into consistent, recurring earnings. The next two quarters, and especially the Permian revenue recognition, should tell investors a great deal. This article is for information only and does not constitute investment advice.

FAQs: